0 605

Cited 53 times in

Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

DC Field Value Language
dc.contributor.author김경식-
dc.contributor.author성진실-
dc.contributor.author최기홍-
dc.contributor.author최진섭-
dc.contributor.author한광협-
dc.contributor.author한대훈-
dc.contributor.author정재욱-
dc.date.accessioned2019-12-18T00:21:31Z-
dc.date.available2019-12-18T00:21:31Z-
dc.date.issued2018-
dc.identifier.issn1068-9265-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/173013-
dc.description.abstractBACKGROUND: Locally advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) has a poor oncological outcome. This study evaluated the oncological outcomes and prognostic factors of surgical resection after downstaging with localized concurrent chemoradiotherapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC). METHODS: From 2005 to 2014, 354 patients with locally advanced HCC underwent CCRT followed by HAIC. Among these patients, 149 patients with PVTT were analyzed. Exclusion criteria included a total bilirubin ≥ 2 mg/dL, platelet count < 100,000/μL, and indocyanine green retention test (ICG R15) > 20%. During the same study period, 18 patients with PVTT underwent surgical resection as the first treatment. Clinicopathological characteristics and oncological outcomes between groups were compared. RESULTS: Among 98 patients in the CCRT group, 26 patients (26.5%) underwent subsequent curative resection. The median follow-up period was 13 months (range 1-131 months). Disease-specific survival differed significantly between the resection after localized CCRT group and the resection-first group {median 62 months (95% confidence interval [CI] 22.99-101.01) versus 15 months (95% CI 10.84-19.16), respectively; P = 0.006}. Multivariate analyses showed that achievement of radiologic response was an independently good prognostic factor for both disease-specific survival (P = 0.039) and disease-free survival (P = 0.001) CONCLUSIONS: Localized CCRT could be an effective tool for identifying optimal candidates for surgical treatment with favorable tumor biology. Furthermore, with a 26.5% resection rate and 100% response in PVTT for resection after CCRT, our localized CCRT protocol may be ideal for PVTT.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer-
dc.relation.isPartOfANNALS OF SURGICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCarcinoma, Hepatocellular/mortality-
dc.subject.MESHCarcinoma, Hepatocellular/pathology-
dc.subject.MESHCarcinoma, Hepatocellular/therapy*-
dc.subject.MESHChemoradiotherapy/mortality*-
dc.subject.MESHCombined Modality Therapy-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHepatectomy/mortality*-
dc.subject.MESHHumans-
dc.subject.MESHInfusions, Intra-Arterial-
dc.subject.MESHLiver Neoplasms/mortality-
dc.subject.MESHLiver Neoplasms/pathology-
dc.subject.MESHLiver Neoplasms/therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Recurrence, Local/mortality-
dc.subject.MESHNeoplasm Recurrence, Local/pathology-
dc.subject.MESHNeoplasm Recurrence, Local/therapy*-
dc.subject.MESHPortal Vein/pathology*-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Rate-
dc.subject.MESHVenous Thrombosis/mortality-
dc.subject.MESHVenous Thrombosis/pathology-
dc.subject.MESHVenous Thrombosis/therapy*-
dc.titleDownstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorJae Uk Chong-
dc.contributor.googleauthorGi Hong Choi-
dc.contributor.googleauthorDai Hoon Han-
dc.contributor.googleauthorKyung Sik Kim-
dc.contributor.googleauthorJinsil Seong-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorJin Sub Choi-
dc.identifier.doi10.1245/s10434-018-6653-9-
dc.contributor.localIdA00299-
dc.contributor.localIdA01956-
dc.contributor.localIdA04046-
dc.contributor.localIdA04199-
dc.contributor.localIdA04268-
dc.contributor.localIdA04273-
dc.relation.journalcodeJ00179-
dc.identifier.eissn1534-4681-
dc.identifier.pmid30083834-
dc.identifier.urlhttps://link.springer.com/article/10.1245%2Fs10434-018-6653-9-
dc.contributor.alternativeNameKim, Kyung Sik-
dc.contributor.affiliatedAuthor김경식-
dc.contributor.affiliatedAuthor성진실-
dc.contributor.affiliatedAuthor최기홍-
dc.contributor.affiliatedAuthor최진섭-
dc.contributor.affiliatedAuthor한광협-
dc.contributor.affiliatedAuthor한대훈-
dc.citation.volume25-
dc.citation.number11-
dc.citation.startPage3308-
dc.citation.endPage3315-
dc.identifier.bibliographicCitationANNALS OF SURGICAL ONCOLOGY, Vol.25(11) : 3308-3315, 2018-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.